Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Invest Dermatol. 2018 Feb 13;138(7):1539–1545. doi: 10.1016/j.jid.2018.01.032

Table 2.

Adverse events of patient enrolled differentiated by severity of adverse event grade.

Adverse Event Any Grade Grade 3–4
Upper resperatory infection 11 (91.6%) 0
Increased bowel movement frequency 4 (33.3%) 0
Blood on Urinalysis 4 (33.3%)
Loose stools 3 (25%) 0
Mild acne 3 (25%) 0
Weight Gain 2 (16.6%) 0
Asymptomatic bacteriuria 2 (16.6%)
Hypertensive Urgency 1 (8.3%) 1 (8.3%)
Bloating 1 (8.3%) 0
Constipation 1 (8.3%) 0
Dizziness 1 (8.3%) 0
Headache 1 (8.3%) 0
Neuropathic pain 1 (8.3%) 0
Vaginal spotting (post menopause) 1 (8.3%) 0
Conjunctivitis 1 (8.3%) 0
Urinary Retention 1 (8.3%) 0
Transaminitis 1 (8.3%) 0